A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
29 July, 2026
TROG to run breast cancer trial in Australia after gaining $2.86m grant
LATEST NEWS: 29 July 2026 TROG Cancer Research is
21 July, 2026
New TROG Scientific Committee Chair-Elect and members bring diverse experience
LATEST NEWS: 21 July 2026 The TROG Scientific Committee